NASDAQ: ILMN

World Must Leverage Genomics to Fight Pandemics, Illumina CEO Says

Article

By

Two years into the pandemic that has killed millions and shaken the global economy, the world still lacks a unified effort to detect and fight future outbreaks using genetic tools, said Illumina Inc. Chief Executive Officer Francis deSouza.

Baby Fitz's Life-Saving Diagnosis Through Whole-Genome Sequencing

How genomics provided critical answers—and in record time—to transform outcomes for a newborn and his family
Article

In June 2019, Christina and Daniel Kettler were barely home from the hospital with their newborn son when they received an urgent phone call. They needed to rush back immediately: A routine screening, called the heel stick test, had revealed that Fitz, their firstborn baby, had Severe Combined Immunodeficiency (SCID). SCID is a rare condition also known as “bubble boy disease.”

Illumina Singapore Receives Best Employer Award for Third Time

Multimedia with summary

Congratulations and thank you to the Illumina Singapore team on having Illumina ranked #1 Best Employer in our industry, and #17 overall, in Singapore by The Straits Times!

John Frank Joins Illumina as Chief Public Affairs Officer

Press Release

SAN DIEGO, April 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of John Frank as the Company's Chief Public Affairs Officer (CPAO). Frank joins Illumina on April 18 from Microsoft Corporation; he will report to Chief Executive Officer Francis deSouza.

Illumina Expands Access to Genomics in Latin America Through New State-of-the-Art Solution Center

Regional Solution Center in São Paulo, Brazil will enable customer access to next-generation sequencing training and expertise to improve patient outcomes
Press Release

SAN DIEGO, April 13, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of its new state-of-the-art Solution Center in São Paulo, Brazil. The choice to bring the facility to Brazil reflects an increasing demand for and interest in clinical genomics, as well as Illumina's longstanding commitment to expanding global access to genomics in Latin America.

Illumina Releases Annual Corporate Social Responsibility Report

Report highlights contributions of genomics to advances in public health and overall health of our planet
Press Release

SAN DIEGO, April 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health. The report details Illumina's role as a champion for patients, communities, people, and the planet.

How Genomics Will Support Gorilla Conservation

An Illumina iConserve project is mapping genetic diversity to identify where confiscated gorillas come from and boost survival rates
Article

Dr. Magdalena Bermejo is calling from a 50-square-meter house deep in a rainforest in the Republic of Congo. Her home and research station on the southwestern border of Odzala-Kokoua National Park, part of the Sabine Plattner African Charities (SPAC) World-Class Field Station Network (WCFS-Network), is one of the few places where large-scale studies of high-density western lowland gorilla populations are still possible.

Join Illumina on World Tuberculosis Day to Raise Awareness and Keep the Fight Up to Eradicate TB

Multimedia with summary

Which infectious disease kills more people in the world than any other? It mutates, mostly impacts your lungs, very contagious in a close household setting, can be asymptomatic and hard to eradicate. Did you want to say COVID?

Can Wastewater Surveillance Protect Public Health?

Biobot Analytics is using wastewater data to predict COVID surges and other outbreaks
Article

Whether we realize it or not, we leave clues to our health every time we use the bathroom.

The excretions we flush down the drain without a second thought offer a treasure trove of data and community health insight to Biobot Analytics. Biobot is the first company in the world to commercialize data from sewage. What we eat, the pathogens we harbor, and the drugs we use all end up in wastewater, and ultimately, that sewage contains a wealth of information about a community’s health.

Pages

Subscribe to NASDAQ: ILMN